UBS Group’s Rallybio RLYB Stock Holding History
Bought
Maintained
Sold
Other funds holding RLYB
ACM
TGA
PBPIA
NCM
AC
RC
UBS Group's RLYB Position: Q2 2026 in Review
UBS Group reduced its Rallybio (RLYB) stake by 98% in Q2 2026, selling an estimated $99.9K and leaving 146 shares worth $2.34K. The position accounts for ﹤0.01% of the portfolio, ranked #9365.
UBS Group first reported a position in RLYB in Q4 2021 and has held it in 17 quarters since. The position peaked at $100K in Q2 2023. 37 funds tracked by Wall St. Rank hold RLYB as of Q2 2026.
- UBS Group held 146 shares of Rallybio worth $2.34K as of Q2 2026.
- UBS Group sold 7,768 Rallybio shares in Q2 2026, an estimated $99.9K.
- Rallybio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9365 holding.
- UBS Group first reported a position in Rallybio in Q4 2021 and has held it in 17 quarters since.
- UBS Group's Rallybio position peaked at $100K in Q2 2023.
- 37 funds tracked by Wall St. Rank held Rallybio as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.